The value in dispute is 100 Mio. EUR. A lawsuit between the same parties regarding a U.S. patent family members of the patent now challenged before the UPC was recently decided by the U.S. Supreme Court in Amgen vs. Sanofi. The U.S. case dealt with the interesting question of enabling disclosure over the full claim scope or, stated differently, the degree to which independent claims may be generalized as compared to the specific embodiments (which were considered to be disclosed in an enabling manner in the U.S. case).

This is a worthy start for the UPC system, which clearly attracts interesting cases.

It is a bit unfortunate that, notwithstanding all efforts to set up a modern, all electronic system, the revocation action appears to have been filed in paper form pursuant to R. 4.2 UPC (UPC CMS not working properly).

Der Beitrag UPC isolated revocation action erschien zuerst auf meier ip.